Related coverage linked through entity extraction aliases.
Feb 16, 2026
The FDA is set to announce decisions in March 2026 on several drug applications, including label expansions for approved therapies and new drug candidates, with some making repeat approval attempts.
Feb 28, 2025
Drug Hunter has opened nominations for the 2025 Molecules of the Year following the announcement of the final Molecules of the Month for 2025. Eligible molecules must have been first disclosed or had a major update in 2025.
Dec 19, 2025
Takeda announced positive Phase 3 results for zasocitinib in adults with moderate-to-severe plaque psoriasis, meeting all 44 endpoints. The company is also conducting a Phase 3 trial in pediatric patients.
